Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany



    TORONTO, Sept. 20 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI) today
announced the market launch of its EAA(TM) Endotoxin Activity Assay, a rapid
diagnostic product for sepsis, in Germany through A. Menarini Diagnostics
Deutschland ("Menarini"), a division of the Italian Menarini Group. Sepsis is
the third most common cause of death in Germany with 60,000 victims each year.
The treatment of severe sepsis consumes about one third of intensive care
units' budgets in Germany ((euro) 1.7 billion per year), emphasizing the need
for early detection of sepsis.
    "The German launch represents a significant milestone in the
commercialization of our EAA(TM) rapid sepsis diagnostic and follows several
months of extensive research by our partner Menarini," stated Dr. Paul Walker,
President & CEO of Spectral. "Germany is the largest healthcare market in the
EU and we are quite confident that with Menarini's broad and experienced sales
presence we are well positioned to make a successful entry into this market
and set the stage for expansion into the rest of Europe in 2008."

    Menarini Diagnostics was founded in 1976 as a division of A. Menarini
Industrie Farmaceutiche Riunite of Florence, Italy, a multinational healthcare
company with annual revenues of more than 2.2 billion Euros, with eleven
wholly owned subsidiaries in Austria, Belgium, France, Germany, Greece, Italy,
the Netherlands, Portugal, Spain, United Kingdom and Sweden. Menarini
Diagnostics had 2005 consolidated revenues of approximately 256 million Euros
and currently employs approximately 700 people, 75% of whom are dedicated to
marketing, sales, after-sales service and customer care activities.

    Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral technologies provide accurate and timely
information to clinicians enabling the early initiation of appropriate and
targeted therapy. Current products include Spectral's FDA approved rapid
diagnostic for West Nile Virus (RapidWN(TM)) and its FDA approved rapid
diagnostic for sepsis (EAA(TM)), as well as a range of other biological
reagents.

    Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.

    %SEDAR: 00002006E




For further information:

For further information: At: Spectral Diagnostics Inc., Dr. Paul Walker,
President & CEO, (416) 626-3233 ex. 2100

Organization Profile

Spectral Diagnostics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890